Keyphrases
Sorafenib
100%
Sphingosine Kinase Inhibitor
100%
Anticancer Effect
100%
ABC294640
44%
Lipids
22%
Tumor Growth
22%
Clinical Trials
11%
Oral Administration
11%
DNA Fragmentation
11%
Mitogen-activated Protein Kinase
11%
Cell Growth
11%
Sphingosine-1-phosphate
11%
SphK2
11%
Caspase-3
11%
Signal Transduction Inhibitors
11%
Sphingosine
11%
ERK Phosphorylation
11%
Specific Inhibitor
11%
Tumor Inhibition
11%
Pro-apoptotic
11%
Sphingosine Kinase 1 (SphK1)
11%
Multikinase Inhibitor
11%
Xenograft Model
11%
Growth in Vitro
11%
Synergistic Inhibition
11%
Mammary Adenocarcinoma
11%
Human Pancreatic Adenocarcinoma
11%
Tumor Growth Delay
11%
Pharmacology, Toxicology and Pharmaceutical Science
Sorafenib
100%
Sphingosine Kinase Inhibitor
100%
Tumor Growth
44%
Opaganib
44%
Clinical Trial
11%
Mitogen Activated Protein Kinase
11%
Sphingosine 1 Phosphate
11%
Sphingosine Kinase 2
11%
Pancreas Adenocarcinoma
11%
Caspase 3
11%
Antitumor Activity
11%
Sphingosine
11%
Kidney Carcinoma
11%
Breast Adenocarcinoma
11%
Sphingosine Kinase 1
11%